GlobeImmune, Inc.
GBIM
Rank in Stocks
#35033
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and... GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.
Share Price
$0.0001
Last synced: 2026-11-16
Market Cap
$575.16
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GlobeImmune, Inc. (GBIM)
Category
Healthcare
EPS for GlobeImmune, Inc. (GBIM)
EPS as of March 2016 TTM: $-0.36
According to GlobeImmune, Inc.'s latest financial reports, its current EPS (TTM) is $-0.36. At the end of 2015 the company had an EPS of $-0.48, an increase over its 2014 EPS of $-6.91.
EPS history for GlobeImmune, Inc. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.36 | -25.00% |
| 2015 | $-0.48 | -93.05% |
| 2014 | $-6.91 | -80.61% |
| 2013 | $-35.64 | 69.15% |
| 2012 | $-21.07 | -86.44% |
| 2011 | $-155.37 | 0.44% |
| 2010 | $-154.69 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -4,450.00% |
US
|
|
| $-7.07 | 1,863.89% |
US
|
|
| $-5.29 | 1,369.44% |
AU
|
|
| $12.73 | -3,636.72% |
BE
|
|
| $21.56 | -6,088.89% |
NL
|
Questions about GlobeImmune, Inc.'s earnings per share (EPS)
What is GlobeImmune, Inc.'s earnings per share (EPS)?
GlobeImmune, Inc.'s earnings per share (EPS) over the last twelve months is $-0.36, as of Mar 2016.
What was GlobeImmune, Inc.'s earnings per share (EPS) in 2015?
In 2015, GlobeImmune, Inc.'s earnings per share (EPS) was $-0.48, compared with $-6.91 in 2014.
How has GlobeImmune, Inc.'s earnings per share (EPS) changed since 2010?
From 2010 to 2015, GlobeImmune, Inc.'s earnings per share (EPS) was highest in 2015 ($-0.48) and lowest in 2011 ($-155.37).
How does GlobeImmune, Inc.'s earnings per share (EPS) compare with similar companies?
GlobeImmune, Inc.'s earnings per share (EPS) ($-0.36) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.